Mitoxantrone (MTO) is a topoisomerase inhibitor used in the treatment of breast cancer, hepatocellular carcinoma, ovarian cancer, non-Hodgkin’s lymphoma, and leukemia [38–40]. This evidence concerns the gene SELENBP1 and breast carcinoma.